Identifying Therapeutic Targets of Accelerated Sarcopenia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Identifying Therapeutic Targets of Accelerated Sarcopenia (NCT03118050), a randomized na study. The primary outcome is Leg Lean Mass.

2. Clinical Question

3. Trial Design

The registry describes a randomized, single-masked, parallel trial and lists the study as completed. The sponsor is The University of Texas Medical Branch, Galveston. The recorded enrollment is 95. The listed conditions are sarcopenia, diabetes mellitus, and aging. The trial began on 2017-05-28, and primary completion is recorded as 2023-08-21. These registry entries describe the study record, but do not by themselves establish how participants were allocated to each reported group or which people were masked.

The arms cover distinct research settings. The resistance-training arm enrolled participants with type 2 diabetes who underwent 3 months of training, with muscle size, strength, and response to a low dose of amino acids measured before and after training. Its description refers to comparison with previously obtained results in healthy older subjects; those results are not reported in the registry record.

The remaining arms involve short-term bed rest. They distinguish healthy participants and participants with type 2 diabetes, and describe low-dose amino acids, high-dose amino acids, or physical therapy. The PT arms specify intensive physical therapy, while other bed-rest descriptions specify standard-of-care physical therapy. The primary outcome results report a mean and standard deviation for each arm, with different numbers of participants contributing to those reported arm summaries.

Although the registry labels the study randomized, the record does not report the randomization procedure, allocation ratio, or masking details beyond the single-masked designation. It also does not report a fuller protocol description explaining the relationship among the different study settings. The posted primary-outcome analysis is an ANOVA across the six bed-rest groups, rather than an analysis that includes the resistance-training group.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 7 groups are shown.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Only the first 6 of 8 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Leg Lean Mass, measured over Change from baseline to up to 3 months.

Leg lean mass is the primary endpoint. The registry defines it as change from baseline to up to 3 months, measured by DEXA, and reports the outcome as a mean in kilograms with standard deviations. Leg lean mass is a body-composition measure focused on lean tissue in the legs. Expressing the outcome as change makes the result describe movement from each participant's baseline measurement over the stated follow-up period, rather than a single follow-up value alone.

As a general statistical point, a continuous outcome such as leg lean mass can be summarized by a group mean, while the standard deviation describes how dispersed individual measurements are around that mean. A positive mean change indicates an average increase relative to baseline; a negative mean change indicates an average decrease. Neither summary alone describes every participant's trajectory, and the standard deviation is not a confidence interval for the group mean.

Leg lean mass is relevant to this study's stated focus on muscle size and loss associated with aging, diabetes, and hospitalization-related bed rest. The registry also lists knee extension strength as a secondary outcome and reports four outcome measures overall, but further secondary-outcome results are not included in the record summarized for this analysis. The registry does not report the DEXA procedures, the exact follow-up schedule within the stated timeframe, or a clinically meaningful threshold for interpreting changes in kilograms. Thus the endpoint offers a measure of change in leg lean mass, but the record alone does not establish how a particular change should be interpreted clinically.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary outcome is continuous, so the registry reports a mean change and standard deviation for each arm. These describe the location and spread of observed changes in leg lean mass. A mean is sensitive to the values of all observations, while a standard deviation provides information about how much individual observations vary around that mean. Neither statistic, by itself, establishes a treatment effect or the precision of a comparison.

What does the ANOVA test?

The reported analysis is an ANOVA across the six bed-rest groups. In general, analysis of variance compares variation among group means with variation among observations within groups. Its overall test addresses whether the group means can be treated as equal under the model, rather than estimating every pairwise difference separately. The record gives p <0.01 for this analysis. This indicates that the omnibus test result is inconsistent with a common-mean model at conventional significance thresholds, but it does not reveal the pattern of the differences.

An omnibus result does not show whether a particular amino-acid condition differs from another, whether healthy participants differ from participants with type 2 diabetes, or whether a physical-therapy group differs from another bed-rest group. Those questions require specified contrasts or follow-up analyses. No such estimates or tests are reported in the registry record. The analysis group list contains the six bed-rest arms and excludes the resistance-training arm.

How should the means and standard deviations be read?

The arm means are changes in kilograms from baseline to up to 3 months. A negative mean represents an average decrease, and a positive mean represents an average increase. The standard deviation describes between-participant dispersion, not uncertainty in the estimated mean. A confidence interval, if reported, would instead express uncertainty around an estimate under a stated method. Confidence intervals for these arm means and for between-group contrasts are not reported in the registry record.

Group sizes matter for precision: in general, estimates based on fewer observations tend to be less precise, although the actual uncertainty also depends on variability and the analysis. Here, the outcome summaries report different arm sizes and different standard deviations. These differences make it especially important not to infer comparative precision from the means alone. No confidence intervals are available to quantify the uncertainty for the group means or their differences.

Why can over-dispersion matter?

As a general concept, over-dispersion occurs when variation in observed outcomes is greater than a statistical model expects. When a model does not account for that extra variation, its standard errors may be too small and its tests may appear more certain than warranted. This primary outcome is continuous, and the registry reports an ANOVA; it does not report evidence of over-dispersion or describe a diagnostic assessment. It would therefore be inappropriate to claim that over-dispersion occurred in this analysis. The broader point is that model assumptions and variability should be considered when interpreting any inferential result.

What can a recalculation establish?

A recalculation from posted summary statistics can sometimes provide a simple, unadjusted comparison between two groups. Such a calculation would not replace a sponsor's analysis, which may use a different model, analysis population, or adjustment. In this record, values are missing or not estimable for a two-arm comparison of the continuous endpoint, so a recalculated two-arm estimate is not available. No new contrast or p-value should be inferred from the arm means and standard deviations alone. The registry's reported omnibus ANOVA remains the available inferential analysis for the listed bed-rest groups.

How should planning illustrations be interpreted?

General sample-size calculations use assumptions about the effect to detect, the significance level, allocation, and statistical model. The planning assumptions associated with the posted illustration specify a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect expressed as a stated fraction of the observed effect. Such values are planning illustrations based on the observed effect, not the trial's original design justification and not observed power. The record does not report the original sample-size justification. A sample-size calculation cannot show whether a completed study had a particular probability of detecting its observed result, and no such interpretation should be attached to a planning illustration.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Resistance Training in Type 2 Diabetes (T2DM)", "Bed Rest in Healthy Subjects, Low-dose Amino Acids", "Bed Rest in Healthy Subjects, High-dose Amino Acid", "Bed Rest in Type 2 Diabetes (T2DM), Low-dose Amino", "Bed Rest in Type 2 Diabetes (T2DM), High-dose Amin", "Bed Rest in Healthy Subjects, Physical Therapy (PT")
n   <- c(15, 7, 5, 6, 5, 6)
m   <- c(0.35, -0.55, -0.8, -0.44, -0.66, -0.59)
sp  <- c(0.74, 0.42, 0.44, 0.32, 0.31, 0.73)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Resistance Training in Type 2 Diabetes (T2DM)  15  0.350  0.740  -0.060  0.760
CARM  Bed Rest in Healthy Subjects, Low-dose Amino Acids  7  -0.550  0.420  -0.938  -0.162
CARM  Bed Rest in Healthy Subjects, High-dose Amino Acid  5  -0.800  0.440  -1.346  -0.254
CARM  Bed Rest in Type 2 Diabetes (T2DM), Low-dose Amino  6  -0.440  0.320  -0.776  -0.104
CARM  Bed Rest in Type 2 Diabetes (T2DM), High-dose Amin  5  -0.660  0.310  -1.045  -0.275
CARM  Bed Rest in Healthy Subjects, Physical Therapy (PT  6  -0.590  0.730  -1.356  0.176

11. Analyses Reported by the Sponsor

The registry reports the sponsor's analysis as an ANOVA across the six bed-rest groups, with p <0.01. It does not report a numerical estimate of an overall effect, a confidence interval, or pairwise results. The reported p-value therefore supports an omnibus interpretation only: the analysis found evidence of variation among the means considered, without identifying which group comparisons explain it.

A recalculated two-arm comparison is not available because values are missing or not estimable for that continuous-endpoint comparison. The posted means and standard deviations do not, on their own, supply the missing comparison result. The registry record does not flag a discrepancy between the sponsor analysis and a recalculation. Accordingly, there is no competing recalculated result to set alongside the sponsor's ANOVA. The reported sponsor analysis is the inferential result available for the six bed-rest groups, while the arm means remain descriptive summaries.

The record does not explain whether the ANOVA included covariate adjustment, how missing outcome data were handled, or which analysis population was used. Without those details, the reported result can be described accurately but not reconstructed or fully audited from the posted summaries. It should not be expanded into a claim that a specific amino-acid dose or physical-therapy condition differs from another.

12. Multiplicity, Missing Data and Analysis Populations

The registry reports four outcome measures overall and lists knee extension strength as a secondary outcome. The available primary result is an ANOVA across six bed-rest groups. The record does not report whether the primary and secondary outcomes were tested under a prespecified multiplicity strategy, whether the six-group analysis was followed by planned contrasts, or whether any adjustment was made for multiple testing. When several outcomes or comparisons are considered, the chance of at least one apparently unusual result can increase; multiplicity procedures are one way to address that issue. This is a general statistical concern, not evidence that a particular adjustment was required or performed in this trial.

Missing-data methods are not reported in the registry record. The outcome summaries give arm-specific participant counts, but the record does not state why those counts differ from the overall enrollment, whether any participants lacked measurements, or how incomplete baseline or follow-up values were handled. It also does not report whether the analysis used observed cases, imputation, or another approach. The counts should therefore be read as the numbers reported for the outcome summaries, not as a complete account of outcome availability.

The analysis population is not described. The registry does not say whether the primary analysis followed assigned groups, included only participants who completed the intervention, or used another population definition. Although the overall study is labelled randomized, that label does not establish which analysis population was used for the posted ANOVA.

These gaps limit interpretation of both the p-value and the descriptive results. They do not demonstrate that missing data or multiplicity changed the findings, but they prevent readers from assessing those issues from the registry record. A protocol or fuller statistical report would be needed to understand the planned outcome hierarchy, analysis populations, handling of incomplete data, and any adjustment for multiple comparisons.

13. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The adverse-event record reports no serious adverse events among participants at risk in any of the listed groups. For non-serious adverse events, it reports zero affected participants in every group except the type 2 diabetes physical-therapy group, where one participant was affected. The record reports one death in the healthy-participant high-dose amino-acid bed-rest group and no deaths in the other listed groups.

These figures are counts in the registry's adverse-event summaries, not estimates of comparative risk. The groups have different numbers at risk, and the record does not provide statistical comparisons, confidence intervals, or a basis for attributing an event to an intervention. The relationship of the reported death and non-serious event to study participation is not reported in the registry record. The adverse-event reporting period and further event descriptions are also not reported. The absence of recorded serious adverse events in these summaries should not be interpreted as proof that no serious events occurred outside the recorded reporting process.

14. What the Result Does, and Does Not, Mean

The posted results describe change in leg lean mass across groups studying resistance training or bed rest in healthy participants and participants with type 2 diabetes. The bed-rest group means are negative, while the resistance-training group mean is positive. The registry reports an omnibus ANOVA among the six bed-rest groups with p <0.01. Together, these data describe the observed arm summaries and a reported statistical difference somewhere among the means tested.

They do not establish which bed-rest groups differ from one another, how large any pairwise difference is, or how precisely any such contrast is estimated. The record does not provide pairwise estimates or confidence intervals. The omnibus test does not compare the resistance-training arm with the bed-rest arms, and the resistance-training group is not included in the reported ANOVA. The arm means should therefore not be treated as evidence from a direct statistical comparison between resistance training and bed rest.

The record also does not explain whether results reflect the original randomized allocation, how missing measurements were handled, or what analysis population was used. Those omissions matter because the posted arm summaries do not account for the difference between the total enrollment and the numbers reported for each outcome group. No clinical threshold for interpreting changes in leg lean mass is reported, either.

More generally, a statistical result is not by itself a clinical conclusion. The reported p-value does not show the size or practical importance of a difference, and the mean changes do not show every participant's response. The trial's stated purpose is to investigate mechanisms related to muscle loss, strength, and physical function, but the leg lean mass results alone do not answer every question about those processes. They provide a limited account of the registry-reported outcome, with important comparisons and analysis details not reported in the registry record.

15. Why This Trial Matters Statistically

This trial is statistically notable for combining multiple research settings within one registry record: resistance training in participants with type 2 diabetes and bed rest in healthy participants or participants with type 2 diabetes, with amino-acid or physical-therapy conditions. That structure makes the distinction between descriptive group summaries and inferential comparisons especially important. A collection of means can look directly comparable while representing different participant groups and study conditions.

The reported ANOVA addresses the six bed-rest groups as a set. Its p-value indicates an omnibus finding, but it does not resolve the clinically or scientifically specific questions that readers may naturally ask about dose, diabetes status, or physical therapy. Answering those questions requires defined contrasts, estimates of their size, and uncertainty measures. Those are not reported in the registry record.

The varied arm sizes and standard deviations also illustrate why a single mean is not enough to characterize evidence. Means describe average change; standard deviations describe dispersion; confidence intervals would describe uncertainty around estimates. The latter are absent for the primary summaries. Clear distinction among these quantities helps prevent overinterpretation of an arm's apparent direction or magnitude.

Finally, this record shows why trial interpretation depends on analysis details as well as outcomes. The registry identifies the design as randomized, yet does not report the allocation procedure, analysis population, missing-data approach, or multiplicity strategy. Those omissions do not invalidate the posted summaries, but they constrain what can be concluded from them. Statistically, the most defensible reading separates the descriptive changes from the one reported omnibus test and leaves unreported comparisons unresolved.

16. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary outcome record reports arm-level means, standard deviations, and participant counts, but it does not provide confidence intervals for the means or comparisons. The only stated inferential analysis is an ANOVA across six bed-rest groups, with p <0.01. The record does not report the test statistic, degrees of freedom, model details, post-analysis contrasts, or adjusted pairwise estimates. Consequently, the size and precision of specific group differences cannot be assessed from the posted results.

The overall enrollment is 95, while the primary outcome summaries report different, smaller arm counts. The registry does not explain this difference, describe missing measurements, or state how incomplete data were handled. It also does not identify the analysis population. This leaves uncertainty about which enrolled participants contributed to each summary and how the available results relate to the stated randomized design.

The intervention settings differ across groups. The reported ANOVA includes the bed-rest groups but excludes the resistance-training group, so it cannot serve as a direct test of resistance training versus bed rest. The record's reference to comparison with earlier results in healthy older subjects does not include those results or a numerical comparison. Further, randomization procedures, allocation details, and the identity of the masked party are not reported.

The registry does not report a multiplicity plan, the analysis of the listed secondary outcome, or a clinically meaningful threshold for change in leg lean mass. Adverse-event details are limited to counts; event relatedness and reporting period are not reported. These are limitations of the information available in the registry record. They restrict interpretation but do not establish that the design or analysis was inadequate.

17. Related Tutorials

18. Related Statistical Calculators

19. Sources

• ClinicalTrials.gov: Identifying Therapeutic Targets of Accelerated Sarcopenia — NCT03118050.
• Registry record last updated 2025-12-05; status last verified 2025-11.
• Results first posted 2025-12-05.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

20. Record Summary

NCT03118050, “Identifying Therapeutic Targets of Accelerated Sarcopenia,” is listed as a completed randomized, single-masked, parallel study sponsored by The University of Texas Medical Branch, Galveston. Recorded enrollment is 95. The study includes resistance training in participants with type 2 diabetes and bed-rest groups involving healthy participants or participants with type 2 diabetes.

The primary outcome is change in leg lean mass, measured by DEXA, from baseline to up to 3 months. The registry reports group means and standard deviations and an ANOVA across six bed-rest groups with p <0.01. It does not report pairwise comparisons, confidence intervals, or enough analysis details to determine the source and precision of specific differences. The resistance-training group is not included in the stated ANOVA.

Missing-data handling, analysis population, multiplicity strategy, and detailed randomization procedures are not reported in the registry record. The adverse-event summaries report no serious adverse events, one non-serious event in the type 2 diabetes physical-therapy group, and one death in the healthy high-dose amino-acid bed-rest group.